Peer Reviewed

Proton-Pump Inhibitors

PPIs May Improve Glycemic Control in People With Diabetes

The use of proton pump inhibitor (PPI) in individuals with diabetes may improve glycemic control, according to the results of a recent systematic review and meta-analysis.

To examine the effects of PPI therapy in this population, the researchers used data from 7 studies (n = 342) comparing glycosylated hemoglobin (HbA1c) or fasting blood glucose among individuals treated with and without PPIs as an add-on to standard therapy. Also included were 5 studies (n = 244,439) on the risk of incident diabetes among individuals taking PPI.

The results indicated that add-on PPI therapy was associated with a significant decrease in HbA1c (weighted mean difference (WMD) -0.36%; 95% CI, -0.68 to -0.05), and fasting blood glucose (WMD -10.0 mg/dL; 95% CI, -19.4 to -0.6), when compared to standard therapy. In addition, the use of PPI did not decrease the risk of incident diabetes (95% CI, 0.89 to 1.34).

“Add-on PPI improved glycemic indices among individuals with diabetes but did not alter the risk of incident diabetes,” the researchers concluded. “The effects of PPI on glycemic control should be considered when prescribing antacids to patients with diabetes.”


—Leigh Precopio



Peng CCH, Tu YK, Lee GY, et al. Effects of proton pump inhibitors on glycemic control and incident diabetes: a systematic review and meta-analysis. J Clin Endocrinol Metab. Published online June 30, 2021. doi: 10.1210/clinem/dgab353